Explore educational content from VCCC lectures, symposia and conferences to keep abreast of the latest developments.
This event showcases how nurse-led research improves quality and safety of cancer care and clinical outcomes.
Associate Professor John McGhee and Professor Maria Kavallaris AM discuss the pre-clinical trial studies on nanoparticle drug delivery systems and the promise of new forms of targeted cancer treatment.
Research into the effectiveness of the HPV vaccine has shown than there has been a dramatic decline in the rates of human papillomavirus, the infection that causes about 99.9 per cent of cervical cancers. Because of the vaccine’s success, the International Papillomavirus Society has stated that cervical cancer could soon be eliminated as a public health problem. We invite you to hear Professor Suzanne Garland AO, member of the International Papillomavirus Society – the world’s leading cervical cancer and HPV research group share her expertise on the topic.
A cancer diagnosis can have significant financial effects on patients, impact for their family, employment, lifestyle and future planning. Today we will learn about the out-of-pocket costs people experience, the unequal distribution of those costs and the impacts which extend to carers and families.
Helen Johnson is a Urology Oncology Clinical Nurse Specialist based at The Christie Hospital in Manchester UK which is the largest single site cancer centre in Europe. She specialises in prostate cancer with a special interest in survivorship and has been leading on redesigning after care pathways across the city.
Mr Rami Rahal is Executive Director of the Cancer Control at the Canadian Partnership Against Cancer (CPAC), an independent organization funded by the Canadian federal government to advance national priorities on cancer control across the country. At CPAC, Rami leads a portfolio that includes System Performance, Data Integration and Research.
A story of patient-led cancer research really exemplifies the power and importance of consumer activity in cancer research. Rare cancers collectively cause more cancer deaths in Australia than any single cancer type. Today we will learn about the NOMINATOR trial, an innovative patient-driven clinical trial exploring genomic profiling of rare cancers.
An emergence framework for carcinogenesis - Dr Elizabeth Sigston and Professor Bryan Williams, Monash University
Exercise for medicine cancer - Associate Professor Prue Cormie, Ed-med Cancer
Resistance to immunotherapies - Dirk Schadendorf
Director and Chair, Department of Dermatology, Skin Cancer Centre
Director, Westdeutsches Tumorzentrum (WTZ) and Comprehensive Cancer Centre (CCC)
Establishing a translational surgical research program in an academic cancer centre - Dr Chandrajit P Raut
Brigham and Women's Hospital
Dana-Farber Cancer Institute
Harvard Medical School
"10% of the time, it works every time" - Dr Glenn Begley
New frontiers in PET/CT molecular imaging: Lung and Prostate Cancers - Eyal Mishani, Hadassah Hebrew University Hospital, Jerusalem
Collaborative Radiology Oncology Trials: Do or Die - Associate Professor Farshad Foroudi
President, Trans Tasman Radiation Oncology Group
Director, Austin Health Radiation Oncology
Investigating the contribution of alcohol in breast cancer recurrence and the way in which alcohol recommendations are discussed between clinicians and oncology patients - Dr Anna Boltong, VCCC Associate Director
Palliative Care: The science behind the art of care - Brian Le
Director of Palliative Care, The Royal Melbourne Hospital and Peter MacCallum Cancer Centre
Creating a culture of autonomous innovation - Dr Amanda Caples, Lead Scientist of Victoria
Crisis, what crisis? Health care funding in the future - Stephen Duckett, Grattan Institute
Novel techniques for epigenomic profiling of single cells and circulating cell-free DNA - Lu Wen, Research Scientist (Co-Pl)
Dr Fuchou Tang's Lab in BIOPIC at Peking University, China
Differentiation therapy for colorectal cancer - John M. Mariadason, PhD
Oncogenic Transcription Laboratory, Olivia Newton-John Cancer Research Institute
Immunotherapy for bladder cancer - Dr Peter Black
Khosrowshahi Family Chair in Bladder Research
Professor, Department of Urologic Sciences
University of British Columbia
Vancouver Prostate Centre
Killing leukemic stem cells - Associate Professor David Curtis
Australian Centre for Blood Diseases
Clinical Haematology, Alfred Hospital
Structural Vulnerability - Dr A Dabscheck
Palliative Medicine Consultant, Western Health